Sector News

Amgen to acquire biopharma firm ChemoCentryx for $3.7bn

August 7, 2022
Life sciences

Amgen has signed a definitive agreement to acquire biopharmaceutical company ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bn.

ChemoCentryx focuses on orally administered therapeutics for the treatment of inflammatory disorders, autoimmune ailments and cancer.

For discovering, developing and marketing such treatments, the company targets the chemokine and chemoattractant systems.

With the takeover, Amgen will gain access to ChemoCentryx ’s Tavneos (avacopan), a therapy for serious autoimmune diseases.

This therapy complements Amgen ‘s expertise in inflammation and nephrology.

An orally administered selective inhibitor of complement component 5a receptor, Tavneos received approval from the US Food and Drug Administration (FDA) in October last year.

It is approved as an adjunctive therapy along with standard therapy for treating adults with severe active ANCA-associated vasculitis, particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Furthermore, Tavneos has received approvals in key markets, including the EU and Japan.

The company also has an oral checkpoint inhibitor for cancer and three early-stage therapy candidates that act on chemoattractant receptors in other inflammatory ailments.

The board of directors of Amgen and ChemoCentryx has granted unanimous approval for the acquisition.

Subject to necessary approvals and closing conditions, the deal is anticipated to conclude in the fourth quarter of this year.

Amgen chairman and CEO Robert Bradway said: “The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with Tavneos, a transformative, first-in-class treatment for ANCA-associated vasculitis.

“We are excited to join in the Tavneos launch and help many more patients with this serious and sometimes life-threatening disease for which there remains significant unmet medical need.”

In October last year, the company acquired all outstanding shares of clinical-stage biotechnology firm Teneobio for $2.5bn.

Source: pharmaceutical-technology.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach